Heron Therapeutics Inc. (NASDAQ:HRTX) – Equities research analysts at Lake Street Capital cut their FY2016 earnings per share estimates for Heron Therapeutics in a research note issued on Wednesday. Lake Street Capital analyst B. Jackson now anticipates that the firm will post earnings per share of ($4.52) for the year, down from their previous forecast of ($4.48). Lake Street Capital has a “Buy” rating and a $45.00 price objective on the stock. Lake Street Capital also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($1.18) EPS, FY2017 earnings at ($3.61) EPS and FY2018 earnings at ($0.29) EPS.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by $0.07.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

A number of other analysts also recently commented on the stock. Jefferies Group restated a “buy” rating and set a $46.00 price target on shares of Heron Therapeutics in a research report on Wednesday, July 27th. Brean Capital restated a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a research report on Saturday, August 13th. Cantor Fitzgerald restated a “buy” rating and set a $41.00 price target on shares of Heron Therapeutics in a research report on Wednesday, August 3rd. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 31st. Finally, Leerink Swann restated an “outperform” rating and set a $33.00 price target on shares of Heron Therapeutics in a research report on Thursday, August 18th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and an average price target of $41.63.

Heron Therapeutics (NASDAQ:HRTX) opened at 19.00 on Friday. Heron Therapeutics has a 1-year low of $13.95 and a 1-year high of $31.32. The firm’s 50-day moving average is $16.31 and its 200-day moving average is $18.17.

Institutional investors have recently made changes to their positions in the company. Morgan Stanley increased its position in Heron Therapeutics by 268.4% in the third quarter. Morgan Stanley now owns 84,014 shares of the biotechnology company’s stock valued at $1,448,000 after buying an additional 61,210 shares during the period. Northern Trust Corp increased its position in Heron Therapeutics by 0.4% in the third quarter. Northern Trust Corp now owns 358,265 shares of the biotechnology company’s stock valued at $6,173,000 after buying an additional 1,286 shares during the period. California State Teachers Retirement System increased its position in Heron Therapeutics by 1.1% in the third quarter. California State Teachers Retirement System now owns 67,332 shares of the biotechnology company’s stock valued at $1,160,000 after buying an additional 700 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Heron Therapeutics by 10.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 830,576 shares of the biotechnology company’s stock valued at $14,311,000 after buying an additional 79,227 shares during the period. Finally, BlackRock Group LTD increased its position in Heron Therapeutics by 4.9% in the third quarter. BlackRock Group LTD now owns 11,345 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 529 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.